Cue Biopharma, Inc.
CUE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645460
In the last 90 days, Cue Biopharma, Inc. insiders filed 0 open-market purchases and 3 sales; 50 institutions reported holding it in 13F filings for Q2 2026, worth $52.2M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Cue Biopharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 3 insiders, $2.04M in total
- Insiders trading
- 3
- Net value
- −$2.04M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Cue Biopharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Sarraf Pasha | Director | 29,195 | Aug 28, 2026 | 3 |
| Garzone Pamela | Director | 18,900 | Aug 28, 2026 | 2 |
| Ray Sumita | Chief Legal Compliance Officer | 118,545 | Aug 17, 2026 | 2 |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer | 48,961 | Aug 17, 2026 | 2 |
| Lin Shao-Lee | Chief Executive Officer | 705,995 | Aug 14, 2026 | 4 |
| Ahlers James M | Chief Financial Officer | 25,500 | Aug 3, 2026 | 1 |
| Borie Dominique Christian | Chief Medical Officer | 31,500 | Jul 15, 2026 | 1 |
| Camardo Daniel A. | Director | 21,800 | Jul 10, 2026 | 2 |
| Meehan Viola Mong | Director | 21,800 | Jul 10, 2026 | 2 |
| Sandercock Colin | SVP, GENERAL COUNSEL | – | Apr 10, 2026 | 2 |
| Warren Lucinda | CHIEF BUSINESS OFFICER | – | Apr 10, 2026 | 2 |
| Baker Daniel G. | CHIEF DEVELOPMENT OFFICER | – | Apr 10, 2026 | 2 |
| Broadfoot Jill Marie | Director | – | Jan 6, 2026 | 1 |
| Kiener Peter A | Director | 357 | Jan 6, 2026 | 1 |
| Morich Frank | Director | 28,000 | Jan 6, 2026 | 1 |
| Verheyen Patrick | Director | – | Jan 6, 2026 | 1 |
| Azam Usman | CHIEF EXECUTIVE OFFICER | – | Oct 2, 2025 | 1 |
| Passeri Daniel R | CHIEF EXECUTIVE OFFICER | 164,578 | Mar 25, 2025 | 0 |
| Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | 14,311 | Mar 25, 2025 | 0 |
| Levisetti Matteo | Chief Medical Officer | – | Mar 25, 2025 | 0 |
| Driscoll Frederick W | Director | – | Jan 3, 2025 | 0 |
| Fox Michael J | Director | – | Jun 7, 2024 | 0 |
| Suri Anish | PRESIDENT AND CSO | 135,638 | Jun 7, 2024 | 0 |
| Nasshorn Patricia | Chief Business Officer | – | Feb 21, 2023 | 0 |
| Howson Tamar D | Director | – | Jan 5, 2023 | 0 |
| Fletcher Aaron G.L. | Director | 940,000Indirect | Jan 5, 2023 | 0 |
| Gray Cameron | Director | 687,049 | Jun 16, 2022 | 0 |
| Pienta Kenneth | Chief Medical Officer | – | Mar 29, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 (view filing)6:22 PM ET | Aug 13 | 4 days | Ray SumitaChief Legal Compliance Officer | SSale | −8.83K | $30.09 | −$265.6K | −6.9%118.5K after | 3 lots |
| Aug 17, 2026 (view filing)6:19 PM ET | Aug 13 | 4 days | Meluzio Michael VincentVP, Prin. Accounting Officer | SSale | −5.63K | $30.09 | −$169.3K | −10.3%49.0K after | 3 lots |
| Aug 14, 2026 (view filing)8:46 PM ET | Aug 12-13 | 2 days | Lin Shao-LeeChief Executive Officer | SSale | −58.3K | $27.58 | −$1.61M | −7.6%706.0K after | 5 lots |
| Jan 2, 2026 (view filing)4:00 PM ET | Dec 30, 2025 | 3 days | Sarraf PashaDirector | PPurchase | +323.9K | $0.308 | +$99.7K | New position323.9K after | 5 lots |
| Dec 18, 2024 (view filing) | Dec 16 | 2 days | Passeri Daniel RCHIEF EXECUTIVE OFFICER | PPurchase | +30.0K | $1.03 | +$30.9K | +22.3%164.6K after | |
| Aug 29, 2023 (view filing) | Aug 25 | 4 days | Suri AnishPRESIDENT AND CSO | PPurchase | +4.00K | $2.76 | +$11.0K | +3.0%135.6K after | |
| Aug 16, 2023 (view filing) | Aug 14 | 2 days | Passeri Daniel RCHIEF EXECUTIVE OFFICER | PPurchase | +3.00K | $2.86 | +$8.58K | +2.3%134.6K after | |
| Mar 27, 2023 (view filing) | Mar 23 | 4 days | Kiener Peter ADirector | SSale | −9.32K | $3.28 | −$30.6K | −96.3%357 after | |
| May 31, 2022 (view filing) | May 27 | 4 days | Morich FrankDirector | PPurchase | +28.0K | $3.75 | +$105.0K | New position28.0K after | |
| May 25, 2022 (view filing) | May 23-24 | 2 days | Fletcher Aaron G.L.Director | PPurchase | +205.0K | $3.47 | +$711.7K | +27.9%940.0K after | 2 lots |
| Apr 4, 2022 (view filing) | Mar 31 | 4 days | Fletcher Aaron G.L.Director | PPurchase | +735.0K | $4.76 | +$3.50M | New position735.0K after | |
| Nov 17, 2021 (view filing) | Nov 15-16 | 2 days | Kiener Peter ADirector | SSale | −20.2K | $17.93 | −$361.7K | −100.0%0 after | 2 lots |
| Nov 17, 2021 (view filing) | Nov 15 | 2 days | Suri AnishPresident and CSO | SSale | −8.00K | $18.05 | −$144.4K | −7.8%94.0K after | |
| Nov 15, 2021 (view filing) | Nov 11 | 4 days | Suri AnishPresident and CSO | SSale | −20.0K | $15.07 | −$301.4K | −17.5%94.0K after | |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Millar Kerri-AnnCHIEF FINANCIAL OFFICER | SSale | −1.25K | $14.21 | −$17.8K | −10.7%10.5K after | |
| Sep 27, 2021 (view filing) | Sep 23 | 4 days | Suri AnishPRESIDENT AND CSO | SSale | −20.0K | $15.23 | −$304.6K | −21.1%74.8K after | |
| Sep 27, 2021 (view filing) | Sep 24 | 3 days | Passeri Daniel RCHIEF EXECUTIVE OFFICER | PPurchase | +3.40K | $14.72 | +$50.0K | +6.5%55.4K after |